Insilico’s rentosertib enters late-stage testing, bringing an aging-informed approach to one of medicine’s most challenging fibrotic diseases.
Insilico Medicine has initiated a Phase III clinical program for rentosertib, its investigational TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), marking the latest milestone for a drug that has become one of the most closely watched programs in AI-enabled drug discovery. The candidate, previously known as ISM001-055 or INS018_055, was both discovered and designed using the company’s Pharma.AI platform and has already reported encouraging Phase IIa data in patients with IPF.
For longevity science, however, this is about more than artificial intelligence. IPF is a quintessential age-related disease, with fibrosis, chronic inflammation, extracellular matrix remodeling and cellular senescence all contributing to its relentless progression. The program therefore sits at the intersection of computational drug discovery and geroscience – a convergence that has become increasingly difficult to ignore.
Longevity.Technology: We have been following rentosertib’s progress for a while now, so today’s announcement feels less like another AI milestone and more like the next test of an increasingly familiar idea – that understanding the biology of aging can reveal therapeutic opportunities that conventional drug discovery has overlooked. Idiopathic pulmonary fibrosis has always sat comfortably within the geroscience canon, driven as it is by fibrosis, chronic inflammation, extracellular matrix remodeling and cellular senescence; if an aging-informed approach can produce a genuinely differentiated medicine here, it strengthens the broader argument that aging biology is becoming a practical framework for drug discovery rather than simply an elegant way of explaining disease. Of course, Phase III has a habit of humbling even the most promising candidates – biology remains gloriously indifferent to investor decks and AI evangelism alike – but reaching this stage is nonetheless notable. Increasingly, the question is no longer whether AI can design molecules more quickly; it is whether combining computational discovery with aging biology can consistently uncover targets worth pursuing in the first place. That may prove to be the more enduring legacy of programs like rentosertib.
A disease with few options
IPF is respiratory medicine at its most unforgiving. The lungs stiffen; scarring accumulates; breath, quite literally, runs out. Current options slow the process but don’t reverse it, and median survival after diagnosis sits at a grim two to four years – a timeline that makes the case for disease-modifying therapy rather better than any press release could.
Rentosertib’s target is TNIK, a serine/threonine kinase with fingers in several fibrotic and inflammatory pathways: Wnt, TGF-β, Hippo/YAP-TAZ, JNK, NF-κB. What’s notable isn’t the kinase itself so much as how Insilico arrived at it. Rather than starting from an established target and working backwards, the company says TNIK emerged from PandaOmics – its AI biology platform, sifting multi-omics data, biological networks and literature for signals that pointed toward aging-relevant disease mechanisms rather than the usual suspects.
From target to molecule
The program has become notable not simply because AI was involved, but because much of its development has been documented through peer-reviewed publications. Target identification, medicinal chemistry, preclinical validation and clinical findings have all appeared in the scientific literature, offering an unusually transparent view of a modern AI-enabled discovery program.
Its Phase IIa GENESIS-IPF study, published in Nature Medicine, enrolled 71 patients across 22 sites in China. Although primarily designed to evaluate safety and tolerability, the trial also reported a dose-dependent improvement in lung function, with patients receiving 60 mg once daily demonstrating a mean increase in forced vital capacity of 98.4 mL after 12 weeks, compared with a decline of 20.3 mL in the placebo group [1]. The findings now provide the rationale for evaluating whether those signals can be reproduced in a larger, longer-duration Phase III study.
Ambition has scaled with the program: 320 patients across 47 centers in China, followed for 52 weeks, with annual rate of FVC decline as the primary endpoint – a shift from the twelve-week signal-finding window of GENESIS-IPF to something closer to how IPF actually behaves over a patient’s year.
Alex Zhavoronkov, PhD, Founder and Chief Executive Officer of Insilico Medicine, said: “Rentosertib is a defining program for Insilico because it represents the full arc of our mission: using AI not only to move faster, but to originate new biology, new chemistry, and new therapeutic opportunities. This program began with the hypothesis that aging biology could help identify powerful targets for major diseases. It has now advanced through target discovery, molecular design, preclinical validation, Phase I safety, randomized Phase IIa clinical data, and into Phase III development. For the AI drug discovery field, this is no longer only a speed story. It is a clinical translation story.”
An aging-informed rationale
Beyond pulmonary fibrosis, Insilico has continued exploring TNIK within the context of aging biology. The company and collaborators have published work suggesting TNIK inhibition demonstrates senomorphic activity in cellular models of senescence, reducing senescence-associated secretory phenotype markers and extracellular matrix remodelling signals. These findings do not establish rentosertib as an anti-aging therapy, but they do add biological context to the decision to pursue TNIK in an age-related disease.
A quiet shift
Perhaps the most interesting aspect of this story lies beyond any single clinical program. As geroscience matures, aging biology is beginning to appear less as an adjacent discipline and more as a source of therapeutic hypotheses that can withstand the scrutiny of mainstream drug development. Whether rentosertib ultimately succeeds or fails will, of course, be determined by Phase III data. Yet the broader direction of travel feels increasingly clear – the biology of aging is no longer waiting politely outside the clinic; it is steadily taking a seat at the drug discovery table.
